FA
ARNA

FCG Advisors’s Arena Pharmaceuticals Inc ARNA Stock Holding History

FCG Advisors’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,060
Closed -$62K – 89
2014
Q2 		$62K Hold
1,060
– – 0.05% 84
2014
Q1 		$66K Buy
+1,060
New +$70.3K 0.05% 82

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FCG Advisors's ARNA Position: Q3 2014 in Review

FCG Advisors sold out of Arena Pharmaceuticals Inc (ARNA) in Q3 2014, closing a stake of 1,060 shares — an estimated $62K sold.

FCG Advisors first reported a position in ARNA in Q1 2014 and held it in 2 quarters. The position peaked at $66K in Q1 2014. 121 funds tracked by Wall St. Rank hold ARNA as of Q3 2014.

  • FCG Advisors reported no remaining Arena Pharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • FCG Advisors sold 1,060 Arena Pharmaceuticals Inc shares in Q3 2014, an estimated $62K.
  • FCG Advisors first reported a position in Arena Pharmaceuticals Inc in Q1 2014 and held it in 2 quarters.
  • FCG Advisors's Arena Pharmaceuticals Inc position peaked at $66K in Q1 2014.
  • 121 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q3 2014.

Based on FCG Advisors's 13F filing for Q3 2014, filed 13 Nov 2014.